‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

Recursion is kicking off a partnering strategy to apply its AI-guided drug discovery platform to new indications with an $80 million Bayer deal that’s tied to a $239 million D round.

“We’ve done a number of collaborations in the past, but the key difference this time is it’s a much larger deal going after a major therapeutic area,” co-founder and CEO Chris Gibson told BioCentury. “It’s transformational for Recursion.” ...